UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Palatin Technologies (PTN)

Palatin Technologies (PTN)
0.2210 x 50 0.2272 x 6
Post-market by (Cboe BZX)
0.2460 +0.0407 (+19.82%) 04/16/25 [NYSE Arca]
0.2210 x 50 0.2272 x 6
Post-market 0.2272 -0.0188 (-7.64%) 19:59 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1920
Day High
0.2584
Open 0.2040
Previous Close 0.2053 0.2053
Volume 4,447,700 4,447,700
Avg Vol 4,294,380 4,294,380
Stochastic %K 9.69% 9.69%
Weighted Alpha -70.66 -70.66
5-Day Change -0.1960 (-44.34%) -0.1960 (-44.34%)
52-Week Range 0.1605 - 2.4800 0.1605 - 2.4800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,339
  • Shares Outstanding, K 26,006
  • Annual Sales, $ 4,490 K
  • Annual Income, $ -29,740 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.89
  • Price/Sales 1.10
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.99
  • Most Recent Earnings $-0.12 on 02/13/25
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 627.25% ( +68.76%)
  • Historical Volatility 289.12%
  • IV Percentile 93%
  • IV Rank 59.44%
  • IV High 1,034.16% on 04/09/25
  • IV Low 30.81% on 05/15/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 95
  • Volume Avg (30-Day) 62
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 4,810
  • Open Int (30-Day) 5,085

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +67.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1605 +53.27%
on 04/11/25
Period Open: 0.7908
0.8710 -71.76%
on 03/17/25
-0.5448 (-68.89%)
since 03/14/25
3-Month
0.1605 +53.27%
on 04/11/25
Period Open: 1.0800
1.3800 -82.17%
on 02/06/25
-0.8340 (-77.22%)
since 01/16/25
52-Week
0.1605 +53.27%
on 04/11/25
Period Open: 1.8700
2.4800 -90.08%
on 05/13/24
-1.6240 (-86.84%)
since 04/16/24

Most Recent Stories

More News
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

SMMT : 23.05 (-6.38%)
RXRX : 5.32 (-5.67%)
PTN : 0.2460 (+19.82%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

VKTX : 23.60 (+2.12%)
RYTM : 61.34 (-1.21%)
NVO : 62.88 (-2.50%)
GPCR : 18.53 (-1.96%)
PTN : 0.2460 (+19.82%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

VKTX : 23.60 (+2.12%)
RYTM : 61.34 (-1.21%)
NVO : 62.88 (-2.50%)
GPCR : 18.53 (-1.96%)
PTN : 0.2460 (+19.82%)
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Receives Notice of Non-Compliance from NYSE American

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023...

PTN : 0.2460 (+19.82%)
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday,...

PTN : 0.2460 (+19.82%)
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
PLN Signs Cooperation with TANESCO to Develop Electricity Ecosystem in Tanzania

PLN Signs Cooperation with TANESCO to Develop Electricity Ecosystem in Tanzania

PTN : 0.2460 (+19.82%)
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END

DRUG : 32.01 (-1.23%)
BDRX : 1.4600 (unch)
LLY : 734.90 (-2.94%)
PTN : 0.2460 (+19.82%)
CRDF : 2.81 (-4.42%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year's End

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

DRUG : 32.01 (-1.23%)
BDRX : 1.4600 (unch)
LLY : 734.90 (-2.94%)
PTN : 0.2460 (+19.82%)
CRDF : 2.81 (-4.42%)
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

PTN : 0.2460 (+19.82%)
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical...

PTN : 0.2460 (+19.82%)
Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023,...

PTN : 0.2460 (+19.82%)

Business Summary

Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling...

See More

Key Turning Points

3rd Resistance Point 0.3387
2nd Resistance Point 0.2985
1st Resistance Point 0.2723
Last Price 0.2460
1st Support Level 0.2059
2nd Support Level 0.1657
3rd Support Level 0.1395

See More

52-Week High 2.4800
Fibonacci 61.8% 1.5940
Fibonacci 50% 1.3203
Fibonacci 38.2% 1.0465
Last Price 0.2460
52-Week Low 0.1605

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro